Accueil   Diary - News   All news Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate

Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate

Nantes, France, July 2, 2018 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, announced today a further update for its Lyme disease vaccine candidate, VLA15. The Company has successfully concluded the end of Phase 1 process for this candidate with the Food and Drug Administration (FDA) and has obtained alignment with regard to its Phase 2 strategy.

 


Valneva is now finalizing the detailed Phase 2 protocol and, subject to requisite regulatory approvals, expects to enter Phase 2 clinical development by the end of 2018.

 

Read the press release